In conclusion, our randomized placebo-controlled trial demonstrated that hypovitaminosis D is common in NAFLD patient and high oral loading dose followed by daily oral doses of vitamin D had beneficial effects on serum ALT levels, hsCRP levels and lipid profile of NAFLD patients. The gene discussed is GPT; the disease is metabolic dysfunction-associated steatotic liver disease.